William Love
Founder bei DESTINY PHARMA PLC
Vermögen: 2 Mio $ am 31.03.2024
Profil
William Guy Love is the founder of Destiny Pharma Plc, a company founded in 1996.
He currently holds the title of Chief Scientific Officer & Executive Director at Destiny Pharma Plc.
In addition to his founding position, Dr. Love also held a former job as a Founding Member at Beam Alliance.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DESTINY PHARMA PLC
6,83% | 18.10.2023 | 6 509 500 ( 6,83% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von William Love
| Unternehmen | Position | Beginn |
|---|---|---|
| DESTINY PHARMA PLC | Founder | 04.03.1996 |
Ehemalige bekannte Positionen von William Love
| Unternehmen | Position | Ende |
|---|---|---|
Beam Alliance
 Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DESTINY PHARMA PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Health Technology |
